At eFFECTOR, our passion is using the best science to develop better medicines to treat cancer. An important part of developing new treatments is conducting clinical trials. eFFECTOR is currently recruiting patients to be part of clinical trials to test potential new products.
Non-germinal center B cell diffuse large B cell lymphoma (Non-GCB DLBCL), including Activated B cell (ABC) DLBCL
Phase 2 study is now enrolling.
Non-small cell lung cancer, bladder cancer, head and neck cancer, hepatocellular cancer and others.
Microsatellite stable colorectal cancer (MSS CRC)
Phase 2 study enrollment is complete.
Metastatic castration-resistant prostate cancer (mCRPC)
Phase 2 study is not yet enrolling.
Phase 1 study not yet enrolling.